ResearchMoz

Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share

Publisher Name » GBI Research
Published Date » 2013-01-22
No. Of Pages » 60

Statins Market to 2018 Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share

Summary

GBI Research, the leading business intelligence provider, has released its latest research, Statins Market to 2018 Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share, which provides insights into the global statins market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Researchs team of industry experts. The report provides an in-depth analysis of the global statins market for dyslipidemia. The report gives insights into the share of generics in the global statins market for the years 2011 and 2018. The report examines the dyslipidemia treatment usage patterns in the US, the top five countries of Europe (The UK, France, Germany, Spain and Italy), and Japan. In addition to the global market landscape for statins, the report also provides details of the geographical distribution of statins sales in the major markets, including the US, the top five countries of Europe, and Japan. The report also includes insights into the statins R&D product pipeline, and explores the competitive landscape, including major players in the statins market. Finally, the report also includes analysis on mergers and acquisitions (M&A) and licensing and co-development deals that have taken place in the statins market.

Statins have dominated the global dyslipidemia therapeutics market for the last few decades. The National Cholesterol Education Program (NECP) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines have recommended the use of statins as the first choice of pharmacotherapy for the treatment of dyslipidemia. The global statins market, valued at $20.5 billion in 2011, is forecast to decline at a negative Compound Annual Growth Rate (CAGR) of 7.2% over the next seven years, to reach $12.2 billion by 2018. The highly consolidated statins market is expected to become increasingly competitive in the forecast period, with the patent expiries of (atorvastatin calcium), Vytorin (Ezetimibe/simvastatin), Lescol (fluvastatin) and Crestor (rosuvastatin), followed by severe generic erosion. GBI Research estimates that the generic sector in the global statins market will grow significantly in the future and will pose tough competition to new molecules.

Scope


  • Data and analysis on the statins market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan. 
  • Annualized market data for the statins market from 2004 to 2011, with forecasts to 2018.
  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment-seeking population, diagnosis population and prescription population.
  • Share of generics in the global statins market.
  • Key drivers and restraints that have had a significant impact on the global statins market.
  • The competitive landscape of the global statins market, including top companies benchmarking. The key companies studied in this report are Pfizer, AstraZeneca, Merck and Novartis.
  • Key M&A activities and licensing agreements that took place in the statins market.

Reasons to buy


  • Align their product portfolio to the markets with high growth potential
  • Build effective strategies to launch their pipeline products by identifying potential geographies
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps
  • Develop key strategic initiatives by studying the key strategies of top competitors 
  • Devise more tailored country-specific strategies through the understanding of key drivers and barriers and the market potential of each indication for different territories
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Statins Market to 2018 - Introduction 8

3 Statins Market to 2018 - Global Statins Market 9
3.1 Introduction 9
3.2 Global Market Forecast 10
3.2.1 Branded and Generic Market Share 12
3.3 Annual Cost of Treatment 13
3.4 Treatment Usage Patterns 14
3.4.1 Disease Population 15
3.4.2 Treatment Seeking Population 15
3.4.3 Diagnosed Population 15
3.4.4 Prescription Population 15
3.5 Drivers and Restraints to the Statins Market 16
3.5.1 Drivers to the Statins Market 16
3.5.2 Restraints to the Statins Market 17
3.6 Major Marketed Products 19
3.6.1 Crestor (rosuvastatin calcium) 19
3.6.2 Lipitor (atorvastatin calcium) 20
3.6.3 Vytorin (ezetimibe/simvastatin) 21
3.6.4 Zocor (simvastatin) 22
3.6.5 Livalo (pitavastatin calcium) 22
3.6.6 Lescol XL (fluvastatin sodium) 23
3.6.7 Pravachol (pravastatin sodium) 24

4 Statins Market to 2018 - Statins Market in the US 25
4.1 Market 25
4.2 Annual Cost of Therapy (ACT) 27
4.3 Treatment Usage Pattern 28
4.3.1 Diseased Population 29
4.3.2 Treatment Seeking Population 29
4.3.3 Diagnosed Population 29
4.3.4 Patients on Statins Therapy 29

5 Statins Market to 2018 - Statins Market in the Top Five Countries of Europe 30
5.1 Market 30
5.2 Annual Cost of Therapy 33
5.3 Treatment Usage Pattern 34
5.3.1 Diseased Population 35
5.3.2 Treatment Seeking Population 35
5.3.3 Diagnosed Population 35
5.3.4 Patients on Statins Therapy 35

6 Statins Market to 2018 - Statins Market in Japan 36
6.1 Market 36
6.2 Annual Cost of Therapy 38
6.3 Treatment Usage Pattern 40
6.3.1 Diseased Population 41
6.3.2 Treatment Seeking Population 41
6.3.3 Diagnosed Population 41
6.3.4 Patients on Statins Therapy 41

7 Statins Market to 2018 - Product Pipeline Anlaysis 42
7.1 Introduction 42
7.2 Pipeline Analysis 42

8 Statins Market to 2018 - Competitive Landscape 43
8.1 Pfizer Inc. 44
8.1.1 Company Overview 44
8.1.2 SWOT Analysis 44
8.2 AstraZeneca PLC (AstraZeneca) 45
8.2.1 Company Overview 45
8.2.2 SWOT Analysis 45
8.3 Merck & Co Inc 46
8.3.1 Company Overview 46
8.3.2 SWOT Analysis 46
8.4 Novartis AG (Novartis) 47
8.4.1 Company Overview 47
8.4.2 SWOT Analysis 47

9 Statins Market to 2018 - Strategic Consolidation 48
9.1 Merger and Acquisition (M&A) Deals 48
9.2 Licensing Deals 49
9.2.1 Licensing Deals by Geography 49
9.3 Co-development Deals 51

10 Statins Market to 2018 - Appendix 52
10.1 Market Definitions 52
10.2 Abbreviations 52
10.3 Bibliography 55
10.4 Research Methodology 56
10.4.1 Coverage 56
10.4.2 Secondary Research 56
10.4.3 Primary Research 57
10.4.4 Therapeutic Landscape 57
10.4.5 Geographical Landscape 60
10.4.6 Pipeline Analysis 60
10.4.7 Competitive Landscape 60
10.5 Expert Panel Validation 60
10.6 Contact Us 60
10.7 Disclaimer 60

List of Tables


Table 1: Statins Market, Global, Revenue ($bn), 2004-2011 10
Table 2: Statins Market, Global, Revenue Forecast ($bn), 2011 -2018 10
Table 3: Statins Market, Global, ACT ($), 2004-2011 13
Table 4: Statins Market, Global, ACT ($), 2011-2018 13
Table 5: Statins Market, Global, Treatment Usage Patterns (million), 2004-2011 14
Table 6: Statins Market, Global, Treatment Usage Patterns (million), 2011-2018 14
Table 7: Statins Market, the US, Revenue ($bn), 2004-2011 25
Table 8: Statins Market, the US, Revenue Forecast ($bn), 2011-2018 25
Table 9: Statins Market, the US, ACT ($), 2004-2011 27
Table 10: Statins Market, the US, ACT ($), 2011-2018 27
Table 11: Statins Market, the US, Treatment Usage Pattern (million), 2004-2011 28
Table 12: Statins Market, the US, Treatment Usage Pattern (million), 2011-2018 28
Table 13: Statins Market, Top Five Countries of Europe, Revenue ($bn), 2004-2011 31
Table 14: Statins Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2011-2018 31
Table 15: Statins Market, Top Five Countries of Europe, ACT ($), 2004-2011 33
Table 16: Statins Market, Top Five Countries of Europe, ACT ($), 2011-2018 33
Table 17: Statins Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2004-2011 34
Table 18: Statins Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2011-2018 34
Table 19: Statins Market, Japan, Revenue ($bn), 2004-2011 36
Table 20: Statins Market, Japan, Revenue Forecast ($bn), 2011-2018 36
Table 21: Statins Market, Japan, ACT ($), 2004-2011 38
Table 22: Statins Market, Japan, ACT ($), 2011-2018 38
Table 23: Statins Market, Japan, Treatment Usage Pattern (million), 2004-2011 40
Table 24: Statins Market, Japan, Treatment Usage Pattern (million), 2011-2018 40
Table 25: Statins Market, Global, Product Pipeline, 2012 42
Table 26: Statins Market, M&A Deals ($m), 2008-2011 48
Table 27: Statins Market, Licensing Deals, 2005-2011 49
Table 28: Statins Market, Co-Development Deals, 2005-2008 51

List of Figures


Figure 1: Statins Market, Global, Revenue ($bn), 2004-2018 10
Figure 2: Statins Market, Global, Generic and Branded Market Share (%), 2011 and 2018 12
Figure 3: Statins Market, Global, ACT ($), 2004-2018 13
Figure 4: Statins Market, Global, Treatment Usage Patterns (million), 2004-2018 14
Figure 5: Statins Market, Global, Drivers and Barriers, 2011 16
Figure 6: Statins Market, the US, Revenue ($bn), 2004 -2018 25
Figure 7: Statins Market, the US, ACT ($), 2004-2018 27
Figure 8: Statins Market, the US, Treatment Usage Pattern (million), 2004-2018 28
Figure 9: Statins Market, Top Five Countries of Europe, Revenue ($bn), 2004-2018 31
Figure 10: Statins Market, Top Five Countries of Europe, ACT ($), 2004-2018 33
Figure 11: Statins Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2004-2018 34
Figure 12: Statins Market, Japan, Revenue ($bn), 2004-2018 36
Figure 13: Statins Market, Japan, ACT ($), 2004-2018 38
Figure 14: Statins Market, Japan, Treatment Usage Pattern (million), 2004-2018 40
Figure 15: Statins Market, Global, Top Companies Market Share (%), 2011 43
Figure 16: Statins Market, Pfizer Inc., SWOT Analysis, 2011 44
Figure 17: Statins Market, AstraZeneca, SWOT Analysis, 2011 45
Figure 18: Statins Market, Merck & Co. Inc., SWOT Analysis, 2011 46
Figure 19: Statins Market, Novartis, SWOT Analysis, 2011 47
Figure 20: Statins Market, Strategic Consolidation, 2005-2011 48
Figure 21: GBI Research Market Forecasting Model 59

Upcoming Reports:

Flexible Electronics Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
Flexible electronics industry combines technical sectors such as polymers, advance materials, flexible displays and more. Each of these sectors are creating new applications in flexible electronics devices, which are applied in medical, advance energy, military, industrial and consumer markets. The flexible electronics industry is driven by the global need to create products which are small, light weight and consume less power. As such devices have flexible structure, low manufacturing cost and are more resistant to shock; they can be integrated with various industrial...
LED Phosphor market - Global Industry size, market share, trends, analysis and forecasts 2012 - 2018
By - Transparency Market Research
The basic element used in LEDs is phosphorous that is responsible for light emission. With increasing use of LEDs in number of applications, there is increased demand for construction of LEDs, and hence increasing requirement for LED phosphor. LEDs offer increased efficiency and lifetime as compared to other light sources and hence, they are highly preferred lighting technology in most of the countries. Although LED industry is booming in demand, there are certain challenges faced by this industry: Unpleasant warmth or coolness Poor color rendering compared...
Corn Starch Industry - Global Market Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
The corn starch market is expected to witness significant growth due to developments in the field of biotechnology and new fermentation organisms that can produce new value-added chemicals.  This industry is growing rapidly and undergoing many technological changes. Research and development for bio-processing of corn starch to produce ethanol and other fermentation products is the current trend. Growing environmental pressure on the use of petroleum products and rising petroleum costs will result in an increase in the production of ethanol from corn starch, thereby...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

One-third of Massachusetts Hospitals Facing Financial Downturn
Sep 14, 2012  
The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...
Now At-Home TB Diagnosis Looks Possible
Sep 14, 2012  
According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples. The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...
China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects
Sep 14, 2012  
Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...
Battling against flu, vaccination necessary for health workers
Sep 14, 2012  
To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease. Health officials...
Japan to Cut Import Duties on Indian Generic Drugs Imports
Sep 14, 2012  
The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...